PT  - JOURNAL ARTICLE
AU  - Witte, David G.
AU  - Brune, Michael E.
AU  - Katwala, Sweta P.
AU  - Milicic, Ivan
AU  - Stolarik, Deanne
AU  - Hui, Yu-Hua
AU  - Marsh, Kennan C.
AU  - Kerwin, James F.
AU  - Meyer, Michael D.
AU  - Hancock, Arthur A.
TI  - Modeling of Relationships between Pharmacokinetics and Blockade of Agonist-Induced Elevation of Intraurethral Pressure and Mean Arterial Pressure in Conscious Dogs Treated with α<sub>1</sub>-Adrenoceptor Antagonists
AID  - 10.1124/jpet.300.2.495
DP  - 2002 Feb 01
TA  - Journal of Pharmacology and Experimental Therapeutics
PG  - 495--504
VI  - 300
IP  - 2
4099  - http://jpet.aspetjournals.org/content/300/2/495.short
4100  - http://jpet.aspetjournals.org/content/300/2/495.full
SO  - J Pharmacol Exp Ther2002 Feb 01; 300
AB  - Fiduxosin is a new α1-adrenoceptor antagonist targeted for the treatment of symptomatic benign prostatic hyperplasia. The purpose of this study was to determine and compare the potencies of the α1-adrenoceptor antagonists terazosin, doxazosin, tamsulosin, and fiduxosin, based on relationships between plasma drug concentrations and blockade of phenylephrine (PE)-induced intraurethral (IUP) and mean arterial pressure (MAP) responses after single oral dosing in conscious male beagle dogs. Magnitude of blockade and plasma concentrations were evaluated at selected time points over 24 h. All drugs produced dose-dependent antagonism of PE-induced IUP and MAP responses. When IUP and MAP blockade effects were plotted against drug plasma concentrations, direct relationships were observed that were well described by the sigmoidal maximal effect model. IUP IC50 values for terazosin, doxazosin, tamsulosin, and fiduxosin were 48.6, 48.7, 0.42, and 261 ng/ml, respectively. MAP IC50 values were 12.2, 13.8, 1.07, and 1904 ng/ml, respectively. Uroselectivity index values, defined as MAP IC50/IUP IC50, were 0.25, 0.28, 2.6, and 7.3, respectively. These results extend previous observations with terazosin in this model, showing that doxazosin exhibits a uroselectivity index comparable to terazosin, consistent with the lack of α1-adrenoceptor subtype selectivity or uroselectivity of these drugs. Tamsulosin, an α1a-/α1d-subtype selective agent, had an index value approximately 10-fold greater than the nonselective drugs. Based on its pharmacokinetic profile and a relative uroselectivity 29-fold greater than the nonselective drugs, fiduxosin is expected to exhibit greater selectivity for urethral compared with vascular α1-adrenoceptors in human and should be a novel, long-acting, uroselective α1-adrenoceptor antagonist. The American Society for Pharmacology and Experimental Therapeutics